Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial

INTRODUCTION: A December 2019 WHO rapid communication recommended the use of 9-month all-oral regimens for treating multidrug-resistant tuberculosis (MDR-TB). Besides the clinical benefits, they are thought to be less costly than the injectable-containing regimens, for both the patient and the healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosu, Laura, Madan, Jason, Worrall, Eve, Tomeny, Ewan, Squire, Bertel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754660/
https://www.ncbi.nlm.nih.gov/pubmed/33371043
http://dx.doi.org/10.1136/bmjopen-2020-042390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754660/
https://www.ncbi.nlm.nih.gov/pubmed/33371043
http://dx.doi.org/10.1136/bmjopen-2020-042390

Ejemplares similares